Half-lifeUnknown in people. Natural MGF lasts minutes; the PEG chain is meant to extend this to many hours or days, but no human data exists.
Vial sizes2 mg
The simple version
What it does
It's meant to help muscles grow and repair after hard training, but that's unproven.
How people take it
People report 200–400 µg as a shot, 1 to 3 times a week after training.
Know this
It has never been tested in people, and a careful lab repeat found no effect.
What it is
When a muscle is worked hard or hurt, it makes a short signal called MGF, which normally breaks down within minutes. PEG-MGF is a lab-made version with an extra chain (PEG) attached so it lasts longer in the body. It has never been tested in human trials.
How it works
The theory is that MGF wakes up the muscle's repair cells and gets them to multiply and build new muscle fiber. The PEG chain is meant to keep it around long enough to reach your muscles from a shot under the skin. Whether MGF really does any of this is disputed.
What people use it for
Building and repairing muscle after training (bodybuilding)
Recovering from injuries
The evidence
Mostly animal studies
Weak. The lab that named MGF reported good early results in cells, but a careful repeat by researchers at two drug companies found no effect on human or mouse muscle cells. No one has studied PEG-MGF in people, so the right dose, safety and benefit are all unknown.
After a training session, often on the days you train the muscle you want to target
Cycle
4–6 weeks, then a break of similar length
Route
Subcutaneous or intramuscular injection
Why: The PEG chain is thought to make it last for days, so people use it a few times a week instead of daily. Taking it after training is meant to match when your body makes MGF on its own. None of this has been tested in people.
Start at the low end, and change one thing at a time. If you take medication or have a health condition, check with a doctor first.
We may earn a commission from these links. Counts include one syringe and two swabs per dose.
Stay safe
Side effects
Redness, pain or lumps where you inject
Signs of low blood sugar (reported, since it's related to the growth signal IGF-1)
Water retention
Headache or tiredness
Possible allergic reaction to PEG (rare, but PEG allergies exist)
Unknown long-term effects
Skip it if
Active cancer or a past cancer (growth signals like this help cells grow)
Pregnant or breastfeeding
Under 18
Known allergy to PEG (polyethylene glycol)
Diabetes or using insulin, unless a doctor is involved
Interactions
Insulin and diabetes drugs: blood sugar may drop further
Stacking with IGF-1 LR3, growth hormone or GH peptides: piles on growth signals, with no safety data
Get help right away for swelling of the face or throat, trouble breathing, chest pain, or a spreading, hot, red injection site.
Storage & legal
Storage
Powder: fridge or freezer. Once mixed with bacteriostatic water: fridge, use within about 3–4 weeks.
Legal status
FDA: Not approved for any use and never tested in human trials. FDA flagged PEG-MGF for safety concerns in compounding reviews in 2023; its compounding status is still under review, so check current rules.
Sport (WADA): Prohibited at all times (S2, growth factors). Mechano growth factors are named on the list.
Common questions
What is the difference between MGF and PEG-MGF?
It's the same peptide, but PEG-MGF has a PEG chain attached so it doesn't break down within minutes. That's why PEG-MGF is used a few times a week, while plain MGF, if used at all, gets injected right into a muscle after training.
Is there good proof it builds muscle?
No. The early good results came from cells in a dish, and a careful repeat by two drug companies found no effect. There are no human studies.
Sources
Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002;522(1-3):156-60. PubMed 12095637
Fornaro M, et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab. 2014;306(2):E150-6. PubMed 24253050
Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176